세계의 유전체학 시장 : 제공별, 제품 유형별, 기술별, 최종사용자별, 서비스 유형별, 용도별, 연구 유형별, 지역별 - 예측(-2029년)

The genomics market is expected to reach USD 66.85 billion in 2029 from USD 42.64 billion in 2024, at a CAGR of 9.4% during the forecast period.

Growth in the genomics market is mainly driven by factors like expanding genomic studies to include the human microbiome, increasing focus on genomics initiatives in low- and middle-income countries, and increased adoption of personalized medicines. However, the initial cost concern to set up the equipment is impacting the growth of the genomics market.

"The reagents, kits, and consumables segment accounted for the largest share by products segment in the genomics market in 2023"

The genomics market is segmented into reagents, kits, and consumables, instruments, and bioinformatics tools in 2023. The reagents, kits, and consumables is the segment with the largest share in products. The reagents, kits, and consumables segment dominates the product type category of the genomics market. They are crucial for almost all genomic workflows, starting from DNA/RNA extraction, amplification, and sequencing up to analysis, and therefore, are needed for nearly all processes involved in either research or clinical applications. Demand is thus triggered by the ever-growing number of genomic experiments conducted in diagnostics, personalized medicine, and drug development. Every one of these workflows demands a constant replenishment of high-quality reagents and kits to make genomic data generation accurate and reliable. Also, the rapid adoption of state-of-the-art technologies such as NGS and PCR accelerates the demand for application-specific reagents and consumables. The steady growth experienced in genomics areas such as healthcare, research, and biotechnology further builds upon the revenue volume realized on the consumable end and maintains its market top-line position..

"The academic & research institutes segment accounted for the largest share by products end-user segment in the genomics market in 2023"

The genomics product market is segmented into hospitals, clinics & diagnostics laboratories, academic & research institutes, pharmaceutical & biotechnologies companies, CROs, and other end users. The hospitals, clinics & diagnostics laboratories are the segment with the largest share in the end-user segment in 2023. The large share of hospitals, clinics & diagnostics laboratories is due to the increased patient engagement in genomic research through citizen science initiatives to democratize data collection and accelerate the discoveries in rare diseases and personalized medicine. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.

"The Asia Pacific region is growing at the highest CAGR in the genomics market from 2024 to 2029."

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the rising demand for precision medicines is supporting the growth. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of genomics technologies in healthcare management and treatment driving the market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-LA Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• QIAGEN (Germany)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Laboratory Corporation of America Holdings (US)
• IQVIA Inc. (US)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Eurofins Scientific (Luxembourg)
• PacBio (US)
• Oxford Nanopore Technologies plc. (UK)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Eppendorf SE (Germany)
• Merck KGaA (Germany)
• BD (US)
• Abbott (US)
• 10X Genomics (US)
• New England Biolabs (US)
• Promega Corporation (US)
• Creative Biogene (US)
• Novogene Co., Ltd. (China)
• Helix, Inc. (US)
• Phalanx Biotech Group (US)
• Polaris Genomics (US)

Research Coverage:

This research report categorizes the genomics market by offerings (products and services), products by type (reagents, kits and consumables, instruments, bioinformatics tools), products by technology (sequencing, PCR, gene editing, flow cytometry, microarrays, in situ hybridization, and other technologies), products by end user (hospitals, diagnostic laboratories, and clinics, academic and research institutes, pharmaceutical and biotechnology companies, CROs, and other end users), services by type (genomics profiling and sequencing services, sample preparation and library preparation service, bioinformatics service), application (drug discovery & development, diagnostics, agriculture and animal research, and other applications), diagnostic applications (oncology, infectious disease, reproductive health, and other diagnostic applications), study type (functional genomics, biomarker discovery, pathway analysis, epigenomics, and other study types) end user by services (hospitals and clinics, academic & research institutes, pharmaceutical & biotechnology companies and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the genomics market. Competitive analysis of top players and upcoming startups in the genomics market ecosystem is covered in this report

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall genomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing government funding for genomics projects, Increasing prevalence of viral and inherited disorders, Advancement in NGS platforms, Growing applications of genomics), restraints (High investment costs), opportunities (Increasing use of genomics in precision medicine, Technological advancements in genomics), and challenges (Handling of large volume of data sets and their analysis, Clinical utility of genomics) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products/services of the genomics market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the genomics market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-LA Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Germany), Agilent Technologies, Inc. (US), Revvity (US), Laboratory Corporation of America Holdings (US), IQVIA Inc. (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech Group (US), Polaris Genomics (US) and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES
• 1.8 IMPACT OF AI/GENERATIVE AI

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET SIZE ESTIMATION
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GENOMICS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: GENOMICS MARKET, BY OFFERING
• 4.3 GENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 GENOMICS MARKET SHARE, BY PRODUCT END USER, 2023

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing government funding for genomics projects
    • 5.2.1.2 Increasing prevalence of viral and inherited disorders
    • 5.2.1.3 Advancements in NGS platforms
    • 5.2.1.4 Growing applications of genomics
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High investment costs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing use of genomics in precision medicine
    • 5.2.3.2 Technological advancements in genomics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Handling of large volumes of data sets and their analysis
    • 5.2.4.2 Clinical utility of genomics
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 REGULATORY SCENARIO
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Sequencing by synthesis
    • 5.6.1.2 Single-molecule real-time sequencing
    • 5.6.1.3 Nanopore sequencing
    • 5.6.1.4 qPCR
    • 5.6.1.5 dPCR
    • 5.6.1.6 Microarray technology
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Cytogenetics
    • 5.6.2.2 Synthetic biology
    • 5.6.2.3 Multiomics
    • 5.6.2.4 Single-cell analysis
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Sample preparation technologies
    • 5.6.3.2 Data analysis
    • 5.6.3.3 Bioinformatics and computational biology
    • 5.6.3.4 Artificial intelligence and machine learning
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY OFFERING
    • 5.7.1.1 Average selling price of key players, by instrument
    • 5.7.1.2 Average selling price of key players, by consumable
    • 5.7.1.3 Average selling price of key players, by service
  • 5.7.2 AVERAGE SELLING PRICE, BY REGION
• 5.8 PATENT ANALYSIS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 THREAT OF SUBSTITUTES
  • 5.12.6 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 CASE STUDY ANALYSIS
• 5.16 TRADE ANALYSIS
  • 5.16.1 IMPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017-2021
  • 5.16.2 EXPORT VALUE FOR FLOW CYTOMETERS (HS CODE 902780), 2017-2021
  • 5.16.3 IMPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022-2023
  • 5.16.4 EXPORT DATA FOR FLOW CYTOMETERS (HS CODE 902780), 2022-2023
• 5.17 IMPACT OF AI ON GENOMICS MARKET

6 GENOMICS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
• 6.3 SERVICES

7 GENOMICS MARKET, BY PRODUCT TYPE

• 7.1 INTRODUCTION
• 7.2 REAGENTS, KITS, AND CONSUMABLES
  • 7.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE PROPEL DEMAND FOR CONSUMABLES, KITS, AND REAGENTS
• 7.3 INSTRUMENTS
  • 7.3.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
• 7.4 BIOINFORMATICS TOOLS
  • 7.4.1 BIOINFORMATICS TOOLS TO HELP TURN RAW DATA INTO MEANINGFUL INSIGHTS

8 GENOMICS PRODUCTS MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 SEQUENCING
  • 8.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH
• 8.3 PCR
  • 8.3.1 RISING DEMAND FOR BIOMARKER DISCOVERY TO PROPEL MARKET GROWTH
• 8.4 GENE EDITING
  • 8.4.1 RISING DEMAND FOR NEWER THERAPEUTIC APPROACH DRIVING GROWTH
• 8.5 FLOW CYTOMETRY
  • 8.5.1 RISING DEMAND FOR FLOW CYTOMETRY FOR AGRIGENOMICS TO DRIVE MARKET GROWTH
• 8.6 MICROARRAYS
  • 8.6.1 RISING ADOPTION OF HIGH THROUGHPUT TECHNOLOGIES LIMITING MARKET GROWTH
• 8.7 IN SITU HYBRIDIZATION
  • 8.7.1 INCREASING DEMAND FOR PRECISE GENE EXPRESSION ANALYSIS DRIVING GROWTH OF SEGMENT
• 8.8 OTHER TECHNOLOGIES

9 GENOMICS PRODUCTS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
  • 9.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
• 9.3 ACADEMIC AND RESEARCH INSTITUTES
  • 9.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
• 9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 9.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS IS DRIVING GROWTH
• 9.5 CROS
  • 9.5.1 RISING COLLABORATION BETWEEN PHARMA COMPANIES AND CROS DRIVING MARKET GROWTH
• 9.6 OTHER END USERS

10 GENOMICS MARKET, BY SERVICE TYPE

• 10.1 INTRODUCTION
• 10.2 GENOMIC PROFILING AND SEQUENCING SERVICES
  • 10.2.1 INCREASED ADOPTION OF SEQUENCING TECHNOLOGIES IN CLINICAL ADOPTION TO SUPPORT MARKET GROWTH
• 10.3 SAMPLE PREPARATION AND LIBRARY PREPARATION SERVICES
  • 10.3.1 INCREASED DEMAND FOR ONCOLOGY AND RARE DISEASE DIAGNOSTICS TO DRIVE MARKET GROWTH
• 10.4 BIOINFORMATICS SERVICES
  • 10.4.1 RISING DEMAND FOR ADVANCED PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH

11 GENOMICS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 DRUG DISCOVERY AND DEVELOPMENT
  • 11.2.1 DRUG DISCOVERY AND DEVELOPMENT TO BE LARGEST APPLICATION IN GENOMICS MARKET
• 11.3 DIAGNOSTICS
  • 11.3.1 RISING DEMAND DUE TO CLINICAL GENOMICS TO SUPPORT MARKET GROWTH
    • 11.3.1.1 Oncology
      • 11.3.1.1.1 Rising demand for targeted therapies to drive market growth
  • 11.3.2 INFECTIOUS DISEASES
    • 11.3.2.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth
  • 11.3.3 REPRODUCTIVE HEALTH
    • 11.3.3.1 Rising focus on genetic diseases to drive market growth
  • 11.3.4 OTHER DIAGNOSTIC APPLICATIONS
    • 11.3.4.1 Rising demand for comprehensive genomic data in clinical genomics to drive market growth
  • 11.3.5 AGRICULTURE AND ANIMAL RESEARCH
    • 11.3.5.1 Genomics to help improve crop productivity
• 11.4 OTHER APPLICATIONS

12 GENOMICS MARKET, BY STUDY TYPE

• 12.1 INTRODUCTION
• 12.2 FUNCTIONAL GENOMICS
  • 12.2.1 INCREASED FOCUS ON FUNCTIONAL GENOME STUDIES TO DRIVE MARKET GROWTH
• 12.3 BIOMARKER DISCOVERY
  • 12.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH
• 12.4 PATHWAY ANALYSIS
  • 12.4.1 RISING PREVALENCE OF COMPLEX DISEASES TO AUGMENT MARKET GROWTH
• 12.5 EPIGENOMICS
  • 12.5.1 RISING INVESTMENTS FOR EPIGENETICS RESEARCH TO BOOST MARKET GROWTH
• 12.6 OTHER STUDY TYPES

13 GENOMICS SERVICES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS, DIAGNOSTIC LABORATORIES, AND CLINICS
  • 13.2.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT DRIVING MARKET GROWTH
• 13.3 ACADEMIC AND RESEARCH INSTITUTES
  • 13.3.1 RISING RESEARCH INTENSITY FOR GENOMICS RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
• 13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO DRIVE GROWTH
• 13.5 OTHER END USERS

14 GENOMICS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 14.2.2 US
    • 14.2.2.1 US expected to dominate market in North America
  • 14.2.3 CANADA
    • 14.2.3.1 Increasing government initiatives in genomics research to boost market growth
• 14.3 EUROPE
  • 14.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 14.3.2 GERMANY
    • 14.3.2.1 Germany to dominate European genomics market
  • 14.3.3 UK
    • 14.3.3.1 Strategic initiatives and funding for genomics research to support market growth
  • 14.3.4 FRANCE
    • 14.3.4.1 Increasing government investment in genomics research to drive growth
  • 14.3.5 ITALY
    • 14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
  • 14.3.6 SPAIN
    • 14.3.6.1 Growing focus on advancements in personalized medicine to support market growth
  • 14.3.7 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 14.4.2 CHINA
    • 14.4.2.1 China to dominate Asia Pacific market during forecast period
  • 14.4.3 JAPAN
    • 14.4.3.1 Rising number of collaborations in genomics to drive market
  • 14.4.4 INDIA
    • 14.4.4.1 Government and private initiatives for genomics to propel market
  • 14.4.5 AUSTRALIA
    • 14.4.5.1 Increased genomics research in Australia to support market growth
  • 14.4.6 SOUTH KOREA
    • 14.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
  • 14.4.7 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 14.5.2 BRAZIL
    • 14.5.2.1 Increased government investments in genomics advancements to drive market in Brazil
  • 14.5.3 MEXICO
    • 14.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 14.6.2 GCC COUNTRIES
    • 14.6.2.1 Saudi Arabia
      • 14.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
    • 14.6.2.2 United Arab Emirates
      • 14.6.2.2.1 Growing collaborations to advance genome sequencing to aid market growth in UAE
    • 14.6.2.3 Rest of GCC Countries
  • 14.6.3 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET IN AFRICA
  • 14.7.2 AFRICA: MACROECONOMIC OUTLOOK

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
• 15.3 REVENUE ANALYSIS
• 15.4 MARKET SHARE ANALYSIS
• 15.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 15.5.1 ILLUMINA, INC.
  • 15.5.2 THERMO FISHER SCIENTIFIC INC.
  • 15.5.3 DANAHER CORPORATION
  • 15.5.4 ROCHE
  • 15.5.5 QIAGEN
• 15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 15.6.1 STARS
  • 15.6.2 EMERGING LEADERS
  • 15.6.3 PERVASIVE PLAYERS
  • 15.6.4 PARTICIPANTS
  • 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
• 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 15.7.1 PROGRESSIVE COMPANIES
  • 15.7.2 RESPONSIVE COMPANIES
  • 15.7.3 DYNAMIC COMPANIES
  • 15.7.4 STARTING BLOCKS
  • 15.7.5 COMPETITIVE BENCHMARKING
• 15.8 VALUATION AND FINANCIAL METRICS OF GENOMICS VENDORS
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 DEALS
  • 15.9.2 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 ILLUMINA, INC.
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products/Services offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 THERMO FISHER SCIENTIFIC INC.
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products/Services offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches
      • 16.1.2.3.2 Deals
      • 16.1.2.3.3 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses and competitive threats
  • 16.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products/Services offered
      • 16.1.3.2.1 Product launches
      • 16.1.3.2.2 Deals
    • 16.1.3.3 MnM view
      • 16.1.3.3.1 Key strengths
      • 16.1.3.3.2 Strategic choices
      • 16.1.3.3.3 Weaknesses and competitive threats
  • 16.1.4 DANAHER CORPORATION
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products/Services offered
      • 16.1.4.2.1 Product launches
      • 16.1.4.2.2 Deals
      • 16.1.4.2.3 Expansions
  • 16.1.5 QIAGEN
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products/Services offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Deals
      • 16.1.5.3.2 Expansions
  • 16.1.6 AGILENT TECHNOLOGIES, INC.
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products/Services offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Deals
      • 16.1.6.3.2 Expansions
  • 16.1.7 REVVITY
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products/Services offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product launches
      • 16.1.7.3.2 Deals
      • 16.1.7.3.3 Expansions
  • 16.1.8 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 16.1.8.1 Business overview
    • 16.1.8.2 Services offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Service launches
      • 16.1.8.3.2 Deals
  • 16.1.9 IQVIA INC.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Services offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Deals
      • 16.1.9.3.2 Expansions
  • 16.1.10 CHARLES RIVER LABORATORIES
    • 16.1.10.1 Business overview
    • 16.1.10.2 Services offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Deals
  • 16.1.11 BIO-RAD LABORATORIES, INC.
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products/Services offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Product launches
      • 16.1.11.3.2 Deals
  • 16.1.12 EUROFINS SCIENTIFIC
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products/Services offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Product launches
      • 16.1.12.3.2 Deals
  • 16.1.13 PACBIO
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products/Services offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Product & service launches
      • 16.1.13.3.2 Deals
      • 16.1.13.3.3 Expansions
      • 16.1.13.3.4 Other developments
  • 16.1.14 OXFORD NANOPORE TECHNOLOGIES PLC.
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products/Services offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Product & service launches
      • 16.1.14.3.2 Deals
  • 16.1.15 TAKARA BIO INC.
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products/Services offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Product & service launches
      • 16.1.15.3.2 Deals
  • 16.1.16 BGI GROUP
    • 16.1.16.1 Business overview
    • 16.1.16.2 Products/Services offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Product & service launches
      • 16.1.16.3.2 Deals
      • 16.1.16.3.3 Other developments
  • 16.1.17 EPPENDORF SE
    • 16.1.17.1 Business overview
    • 16.1.17.2 Products/Services offered
    • 16.1.17.3 Recent developments
      • 16.1.17.3.1 Product & service launches
  • 16.1.18 MERCK KGAA
    • 16.1.18.1 Business overview
    • 16.1.18.2 Products/Services offered
    • 16.1.18.3 Recent developments
      • 16.1.18.3.1 Expansions
  • 16.1.19 BD
    • 16.1.19.1 Business overview
    • 16.1.19.2 Products/Services offered
    • 16.1.19.3 Recent developments
      • 16.1.19.3.1 Product & service launches
      • 16.1.19.3.2 Deals
  • 16.1.20 ABBOTT
    • 16.1.20.1 Business overview
    • 16.1.20.2 Products/Services offered
    • 16.1.20.3 Recent developments
      • 16.1.20.3.1 Product & service launches
  • 16.1.21 10X GENOMICS
    • 16.1.21.1 Business overview
    • 16.1.21.2 Products/Services offered
    • 16.1.21.3 Recent developments
      • 16.1.21.3.1 Product launches
  • 16.1.22 NEW ENGLAND BIOLABS
    • 16.1.22.1 Business overview
    • 16.1.22.2 Products/Services offered
    • 16.1.22.3 Recent developments
      • 16.1.22.3.1 Product & service launches
      • 16.1.22.3.2 Deals
  • 16.1.23 PROMEGA CORPORATION
    • 16.1.23.1 Business overview
    • 16.1.23.2 Products/Services offered
    • 16.1.23.3 Recent developments
      • 16.1.23.3.1 Product & service launches
      • 16.1.23.3.2 Other developments
• 16.2 OTHER PLAYERS
  • 16.2.1 CREATIVE BIOGENE
  • 16.2.2 NOVOGENE CO., LTD.
  • 16.2.3 HELIX, INC.
  • 16.2.4 PHALANX BIOTECH GROUP
  • 16.2.5 POLARIS GENOMICS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS